No Data
LC LOGISTICS (02490.HK) intends to hold a Board of Directors meeting on March 20 to approve the annual performance.
Gelonghui reported on March 10 that LC LOGISTICS (02490.HK) announced that a Board of Directors meeting will be held on March 20, 2025 (Thursday) to consider and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its publication, to consider the recommendation for the payment of a final dividend (if any), and to handle Other matters.
LC Logistics, Inc. Schedules Board Meeting to Approve Annual Results
LC LOGISTICS: DATE OF BOARD MEETING
Zhitong Hong Kong Stock Early Knowledge | Give Consumption Upgrade another boost! Five departments support the consumption upgrade of Autos, electronic products, home products, and more.
The State Administration for Market Regulation and four other departments issued the 'Three-Year Action Plan for Optimizing the Consumer Environment (2025-2027)'. Deeply implement actions to 'increase varieties', 'improve quality', and 'create brands' in the consumer goods industry, promote the construction of quality infrastructure, help enhance the quality linkage of the Industry Chain and supply chain, and strengthen quality, standards, and brand building in areas such as Autos, home appliances, home furnishings, electronic products, textiles and Outfits, and food.
Hong Kong Stock Morning Report | Two departments encourage foreign investment to conduct Private Equity in China. Meituan will pay social insurance for full-time and stable part-time delivery riders.
① Two departments: Encouraging foreign investment to engage in Private Equity in China, guiding more high-quality foreign capital to invest long-term in our listed companies. ② State-owned Assets Supervision and Administration Commission: Accelerating the establishment of an evaluation system for state-owned enterprises to fulfill their Global Strategy missions. ③ Meituan: Will provide social insurance for full-time and stable part-time delivery riders. ④ Federal Reserve minutes: Interest rate cuts require further decline in inflation, and tariff policies add uncertainty.
Gelonghui Selected Announcements (Hong Kong Stocks) | ASCLETIS-B (01672.HK): The first two cohorts of the multiple ascending dose study of the small molecule oral GLP-1R agonist ASC30 in the USA's Phase Ib trial have obtained positive interim results.
【Today's Focus】ASCLETIS-B (01672.HK): The first two cohorts of the multi-dose escalation study of the small molecule oral GLP-1R agonist ASC30 in the USA have achieved positive interim results. ASCLETIS-B (01672.HK) announced that ASC30, taken once daily in the form of an oral tablet for the treatment of obesity (Body Mass Index (BMI): 30-40 kg/m2), has obtained positive interim results in the first two cohorts of a randomized, double-blind, placebo-controlled phase Ib multi-dose escalation (MAD) study (NCT06680440) conducted in the USA. This phase Ib MAD study.
